GlassScriptPhysician profile
Daniel N Castresana
NPI 1770873465
$4,235.06
in general payments reported to CMS, 2019-2025
22 companies · $46.33 in 2025
The $46.33 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $110 · 2021: $300 · 2022: $447 · 2023: $2,885 · 2024: $123 · 2025: $46.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,903 · Food and Beverage: $1,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,902.84 |
| Food and Beverage | $1,151.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,977.50 | 2019-2024 | Orise, Axios, Resolution 360 Ultra Clip |
| Olympus Corporation of The Americas | $659.57 | 2023 | Single Use Electrosurgical Knife Kd-655, Single Use Electrosurgical Hemostatic Forceps |
| Abbvie INC. | $548.05 | 2019-2023 | Skyrizi, Rinvoq, Mavyret |
| Janssen Biotech, INC. | $147.16 | 2021-2025 | Tremfya, Stelara |
| Cook Medical LLC | $125.05 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.00 | 2019-2023 | Xifaxan, Plenvu |
| Celgene Corporation | $92.71 | 2022-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $88.06 | 2019-2023 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $71.38 | 2021-2023 | Entyvio |
| Gilead Sciences, INC. | $62.70 | 2019-2022 | |
| Stryker Corporation | $59.57 | 2023 | 1688 |
| Daiichi Sankyo INC. | $51.16 | 2021-2023 | Injectafer |
| Genzyme Corporation | $42.38 | 2023 | |
| Olympus America INC. | $35.05 | 2023 | Single Use Electrosurgical Snare Sd-400, Evis Eus Endoscopic Ultrasound Center, Evis Exera III Duodenovideoscope |
| Merck Sharp & Dohme LLC | $34.86 | 2022-2023 | Dificid |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $25.19 | 2023 | Dupixent |
| Ferring Pharmaceuticals INC. | $21.73 | 2023 | Rebyota |
| Endogastric Solutions, INC | $20.10 | 2019 | |
| Vivus LLC | $19.53 | 2022 | |
| Ucb, INC. | $17.44 | 2019 | |
| Alfasigma USA, INC. | $14.64 | 2020 | |
| Nestle Healthcare Nutrition INC. | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Castresana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.